162 related articles for article (PubMed ID: 37917742)
1. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Subramanian R; Tang J; Zheng J; Lu B; Wang K; Yant SR; Stepan GJ; Mulato A; Yu H; Schroeder S; Shaik N; Singh R; Wolckenhauer S; Chester A; Tse WC; Chiu A; Rhee M; Cihlar T; Rowe W; Smith BJ
Mol Pharm; 2023 Dec; 20(12):6213-6225. PubMed ID: 37917742
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
3. Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV.
Swanstrom AE; Gorelick RJ; Welker JL; Schmidt F; Lu B; Wang K; Rowe W; Breed MW; Killoran KE; Kramer JA; Donohue D; Roser JD; Bieniasz PD; Hatziioannou T; Pyle C; Thomas JA; Trubey CM; Zheng J; Blair W; Yant SR; Lifson JD; Del Prete GQ
EBioMedicine; 2023 Sep; 95():104764. PubMed ID: 37625266
[TBL] [Abstract][Full Text] [Related]
4. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.
Bester SM; Adu-Ampratwum D; Annamalai AS; Wei G; Briganti L; Murphy BC; Haney R; Fuchs JR; Kvaratskhelia M
mBio; 2022 Oct; 13(5):e0180422. PubMed ID: 36190128
[TBL] [Abstract][Full Text] [Related]
5. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
Margot NA; Naik V; VanderVeen L; Anoshchenko O; Singh R; Dvory-Sobol H; Rhee MS; Callebaut C
J Infect Dis; 2022 Nov; 226(11):1985-1991. PubMed ID: 36082606
[TBL] [Abstract][Full Text] [Related]
6. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
[TBL] [Abstract][Full Text] [Related]
7. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.
Tailor MW; Chahine EB; Koren D; Sherman EM
Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515
[TBL] [Abstract][Full Text] [Related]
8. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
[TBL] [Abstract][Full Text] [Related]
9. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.
Prather C; Lee A; Yen C
Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713
[TBL] [Abstract][Full Text] [Related]
10. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
[TBL] [Abstract][Full Text] [Related]
11. Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model.
Bekerman E; Yant SR; VanderVeen L; Hansen D; Lu B; Rowe W; Wang K; Callebaut C
J Clin Invest; 2023 Aug; 133(16):. PubMed ID: 37384413
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Sun J; Collier AC; Collins C; Shen DD; Ho RJY
J Control Release; 2018 Apr; 275():229-241. PubMed ID: 29432823
[TBL] [Abstract][Full Text] [Related]
13. Lenacapavir: First Approval.
Paik J
Drugs; 2022 Sep; 82(14):1499-1504. PubMed ID: 36272024
[TBL] [Abstract][Full Text] [Related]
14. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
Margot N; Ram R; Rhee M; Callebaut C
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288639
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.
Margot N; Pennetzdorfer N; Naik V; Rhee M; Callebaut C
Antivir Ther; 2023 Dec; 28(6):13596535231220754. PubMed ID: 38085652
[TBL] [Abstract][Full Text] [Related]
16. Clinical targeting of HIV capsid protein with a long-acting small molecule.
Link JO; Rhee MS; Tse WC; Zheng J; Somoza JR; Rowe W; Begley R; Chiu A; Mulato A; Hansen D; Singer E; Tsai LK; Bam RA; Chou CH; Canales E; Brizgys G; Zhang JR; Li J; Graupe M; Morganelli P; Liu Q; Wu Q; Halcomb RL; Saito RD; Schroeder SD; Lazerwith SE; Bondy S; Jin D; Hung M; Novikov N; Liu X; Villaseñor AG; Cannizzaro CE; Hu EY; Anderson RL; Appleby TC; Lu B; Mwangi J; Liclican A; Niedziela-Majka A; Papalia GA; Wong MH; Leavitt SA; Xu Y; Koditek D; Stepan GJ; Yu H; Pagratis N; Clancy S; Ahmadyar S; Cai TZ; Sellers S; Wolckenhauer SA; Ling J; Callebaut C; Margot N; Ram RR; Liu YP; Hyland R; Sinclair GI; Ruane PJ; Crofoot GE; McDonald CK; Brainard DM; Lad L; Swaminathan S; Sundquist WI; Sakowicz R; Chester AE; Lee WE; Daar ES; Yant SR; Cihlar T
Nature; 2020 Aug; 584(7822):614-618. PubMed ID: 32612233
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.
van 't Klooster G; Hoeben E; Borghys H; Looszova A; Bouche MP; van Velsen F; Baert L
Antimicrob Agents Chemother; 2010 May; 54(5):2042-50. PubMed ID: 20160045
[TBL] [Abstract][Full Text] [Related]
18. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model.
Yant SR; Mulato A; Hansen D; Tse WC; Niedziela-Majka A; Zhang JR; Stepan GJ; Jin D; Wong MH; Perreira JM; Singer E; Papalia GA; Hu EY; Zheng J; Lu B; Schroeder SD; Chou K; Ahmadyar S; Liclican A; Yu H; Novikov N; Paoli E; Gonik D; Ram RR; Hung M; McDougall WM; Brass AL; Sundquist WI; Cihlar T; Link JO
Nat Med; 2019 Sep; 25(9):1377-1384. PubMed ID: 31501601
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid Inhibitor.
Di Perri G
Infez Med; 2023; 31(4):495-499. PubMed ID: 38075416
[TBL] [Abstract][Full Text] [Related]
20. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
Darville N; van Heerden M; Mariën D; De Meulder M; Rossenu S; Vermeulen A; Vynckier A; De Jonghe S; Sterkens P; Annaert P; Van den Mooter G
J Control Release; 2016 May; 230():95-108. PubMed ID: 27067365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
